Login to Your Account

Active Biotech's Immunotherapy Anyara Is Down but Not Out

By Cormac Sheridan
Staff Writer

Tuesday, January 29, 2013

Shares in Active Biotech AB fell almost 13 percent Monday on news that its immunotherapy Anyara missed the primary endpoint of a Phase II/III trial in advanced renal cell cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription